Table 3.
Description of the Cohort
| n | ||
|---|---|---|
| Age (years) | ||
| Mean ± SD | 46 ± 15 | 588 |
| Median | 46 | |
| Range | 18–83 | |
| Gender | ||
| Female | 68% | 400 |
| Histology | ||
| Papillary | 85% | 500 |
| Poorly differentiated | 6% | 35 |
| Follicular | 4% | 24 |
| Hurthle cell | 5% | 29 |
| 131I activity for ablation (mCi) | ||
| Mean ± SD | 134 ± 72 | 588 |
| Median | 114 | |
| AJCC stage | ||
| I | 48% | 281 |
| II | 12% | 71 |
| III | 15% | 89 |
| IVa | 12% | 71 |
| IVb | 1% | 5 |
| IVc | 12% | 71 |
| ATA initial risk classification | ||
| Low | 23% | 135 |
| Intermediate | 50% | 294 |
| High | 27% | 159 |
| Response to therapy classification | ||
| Excellent | 34% | 159 |
| Acceptable | 20% | 95 |
| Incomplete | 46% | 217 |
| Stimulated Tg done (first 2 years) | ||
| Yes | 80% | 470 |
| No | 20% | 118 |
| Follow-up Duration (years) | ||
| Mean ± SD | 8 ± 3 | 588 |
| Median | 7 | |
| Range | 1–15 | |
| Clinical status after initial therapy | ||
| No evidence of disease | 52% | 305 |
| Biochemical evidence of persistent disease | 19% | 108 |
| Structural evidence of persistent disease | 28% | 167 |
| Recurrent disease | 1% | 8 |
| Status at final follow-up | ||
| No evidence of disease | 67% | 394 |
| Persistent/recurrent disease | 28% | 165 |
| Death of disease | 5% | 29 |
n = 588.
ATA, American Thyroid Association; SD, standard deviation; AJCC, American Joint Cancer Committee.